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WILLINGNESS TO PAY FOR HIV PREVENTION:
A STUDY OF HIGH- AND LOW-RISK GROUPS
Flanders S
Saint Louis University, School of Public Health,
St. Louis, MO, USA
OBJECTIVE: This purpose of this study was to estimate
the value of I-llV prevention using the contingent valuation
methodology.
METHODS: Two convenience samples of 452 high-risk
individuals (homosexual) and 155 low-risk individuals
(heterosexual) were collected from selected sites across
the state of Missouri. Subjects completed a 60 item ques-
tionnaire on their knowledge, attitudes, beliefs, and sex-
ual behaviors. A series of willingness to pay (WTP) ques-
tions were asked to estimate the value of 98% protection
(i.e., condom use) and 100% protection (i.e., abstinence)
from HIV infection. Additionally, two willingness to be
paid (WTBP) questions were asked to estimate the cost of
behavior change.
RESULTS: The results of the study showed high-risk in-
dividuals placed a greater value on the benefits of HIV
prevention than did individuals at low-risk of HIV infec-
tion. The benefits of condom use against infection from
HIV were valued at $261/month for subjects in the high-
risk sample and $238/month for individuals in the low-
risk sample. The average monetary benefits of abstinence
against HIV infection were estimated at $305/month for
high-risk individuals, compared to $249/month among
individuals in the low-risk sample. Utility for each pre-
ventive behavior (condom use and abstinence) was calcu-
lated using a cost-to-benefit ratio (WTBPIWTP). Utilities
were regressed on demographic and risk variables. A
high-risk individual's utility for 98% protection was as-
sociated with greater exposure risk to HIV and knowl-
edge of an AIDS-related death. The low-risk sample was
not statistically significant, and no statistical relation-
ships were found between independent variables.
CONCLUSIONS: While subject to methodological limi-
tations, the results from this research provide estimates of
the value of HIV prevention strategies. Further research
in the area of WTP and HIV prevention is advocated
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PRESCRIBING PATTERNS FOR TREATMENT OF
UPPER RESPIRATORY INFECTIONS
McLaughlin TP, Lalla DV, Kozma CM
College of Pharmacy, University of South Carolina, Columbia.
SC, USA
OBJECTIVE: To characterize the treatment received by
patients with an upper respiratory infection (URI) in the
South Carolina Medicaid population during 1996. Liter-
ature suggests that antibiotics are commonly prescribed
to patients presenting with symptoms of an URI even
though less than 20% are bacterial in origin. Overuse of
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antibiotics may lead to antibiotic resistance and unneces-
sary costs.
METHODS: Patients with a diagnosis for a cold (lCD-9-
CM 460) or URI (ICD-9-CM 465) between 01/01/96 and
12/31/96 were identified. The study design allowed for
each subject to have multiple diagnoses (episodes). For
each episode, subjects with prescriptions for antibiotics
or symptomatic cold medications within 7 days after the
diagnosis were identified. Any episode within 14 days of
a claim for a bacterial infection, sinusitis or otitis was re-
moved from the study, to rule out the possibility that the
antibiotic was related to another infection.
RESULTS: A total of 22,791 patients was eligible for in-
clusion in the study, incurring 27,847 episodes (Range 1-7
episodes). 9468 (34%) of the episodes were treated with
an antibiotic, accounting for $166,702.33. This rate is
lower than that seen in previous studies; however, our in-
clusion were more stringent than was used previously. If
20% of URIs are bacterial, approximately 3,900 of these
antibiotics were unnecessary. A 25% reduction in the ex-
cess prescriptions would provide a cost savings of
$17,169.75 for South Carolina Medicaid.
CONCLUSION: In spite of comprehensive documenta-
tion arguing against using antibiotics for treatment of
URIs, it appears that they still remain a popular choice
for physicians, with 34% of subjects in this study receiv-
ing antibiotics. This represents an area for cost savings
for the South Carolina Medicaid Program.
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EVALUATION OF THE COST-EFFECTIVENESS
OF MANAGEMENT STRATEGIES IN
CYTOMEGALOVIRUS INFECTION
AND DISEASE
Annemans L', Mauskopfp, Richter N, Chulay J3, Maclaine G3
'HEDM, Belgium; -Research Triangle Institute, Research
Triangle Park, NC, USA; JGlaxo Wellcome, Research
Triangle Park. NC, USA
OBJECTIVE: To develop a decision analytical model for
current and anticipated management of cytomegalovirus
infection and disease in renal transplant patients.
METHODS: We developed a decision analytical model
for the US and UK, containing currently recognized man-
agement strategies for cytomegalovirus infection and dis-
ease in renal transplant patients. The model enables com-
parison of current management strategies, assessment of
anticipated strategies, and the impact of country-specific
practice. Outcomes are expressed as "number of cases
avoided" and "quality-adjusted time without symptoms
or toxicity" (Q-TWIST).
RESULTS: The model indicates that in the UK, for donor
seropositive/recipient seronegative (D+/R-) patients,
prophylaxis with IV ganciclovir cost an additional
27,000 GBP, whereas testing for virus and preemptive
therapy with IV ganciclovir costs an additional 18,000
GBP per case of CMV avoided compared with a "wait
and treat" strategy. Modeling indicates that prophlaxis
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with an efficacious oral drug could reduce these figures to
800 GBP per avoided case. In the US, preemptive therapy
with IV ganciclovir is currently a dominant strategy com-
pared with a "wait and treat" option with IV ganciclovir
($500 less expensive and avoids 18 CMV cases per 100).
This reflects the trend to provide preemptive therapy in
ambulatory settings. There is potential for new oral pro-
phylactic therapies, of similar efficacy to existing thera-
pies, that could result in further cost savings.
CONCLUSIONS: The model demonstrates the cost-
effectiveness of preemptive therapy in ambulatory set-
tings compared with inpatient treatment of CMV disease
(US), suggesting a potential cost-effectiveness of new oral
prophylactic therapies.
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SOCIO·ECONOMIC RELEVANCE OF INPATIENT
TREATMENT OF SKIN AND SOFT TISSUE
INFECTIONS WITH TAZOBACTAMI
PIPERACILLIN 0.5 g/2.0 g IN COMPARISON
WITH AMOXICILLIN/CLAVULANIC ACID,
CEFTRIAXONE, AND CEFOTAXIME
Bruchhausen Y, Rappenhoner B
Institute of Empirical Health Economics, Odenthal, Germany
AmoxicillinlClavulanic acid, Cefotaxime, Ceftriaxone,
and TazobactamlPiperacillin are some of the most pre-
ferred antibiotics to treat skin and soft tissue infection. In
a retrospective analysis, the cost structure was established.
OBJECTIVE: The purpose of this study was to analyze
the medical and economic relevance of above alternative
antibiotic treatments based on multicenter clinical stud-
ies. The comparison of costs and benefits was made on
the basis of a cost-effectiveness analysis.
METHODS: A one-patient model was considered first. In
the one-patient model (Markov model) three states were
constructed: (1) successful therapy, (2) failed therapy be-
cause of ADRs, (3) failed therapy because of lack of efficacy.
Health care costs included in the model were all medical
costs (hospitalization, drug costs, etc.) and indirect costs (ab-
sence from workplace). Indirect costs are calculated with the
human capital approach. Success was defined as the clinical
curing and improvement rate. The success rates were
95% (TazobactamlPiperacillin), 94% (AmoxicillinlClavu-
lanic acid), 90% (Cefotaxime), and 98% (Ceftriaxone).
RESULTS: Therapy with TazobactamlPiperaciliin resulted
in a total cost of DM 3,638 per successfully treated patient.
Therapy with AmoxicillinlClavulanic acid caused total
costs of DM 3,355, therapy with Ceftriaxone caused to-
tal costs of DM 4,221 and therapy with Cefotaxime DM
6,474. Sensitivity analyses were performed to prove the
stability of the results.
CONCLUSION: This cost-effectiveness analysis reveals
that a combination therapy with TazobactamlPiperacillin
incurs lower total costs per successfully treated patient
than Ceftriaxone and Cefotaxime. AmoxicillinlClavu-
lanic acid is the treatment with the lowest costs per suc-
cessfully treated patient.
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COST-EFFECTIVENESS OF L1POSOMAL
DAUNORUBICIN VERSUS L1POSOMAL
DOXORUBICIN IN KAPOSI SARCOMA
Egan T', Henry H2
'Philadelphia College of Pharmacy and Science, Philadelphia,
PA, USA; 2Graduate Hospital, Philadelphia, PA. USA
Kaposi sarcoma (KS) prior to 1980 was a rare indolent
disorder seen in elderly men of Eastern European descent.
Today it is the most common neoplasm seen in patients
with AIDS and has been estimated to contribute to 25%
of the deaths. Chemotherapy is the mainstay treatment of
KS in patients with extensive or progressive disease in-
volving the visceral organs and lymph nodes. Two agents,
liposomal daunorubicin (Daunoxornev) and liposomal
doxorubicin (Doxil"), have replaced treatment with the
toxic combination of ABV.
OBJECTIVE: Develop a decision analysis model compar-
ing the cost-effectiveness of Daunoxome and Doxil in se-
vere KS.
METHODS: Probabilities used to determine patient re-
sponses and complication rates were obtained from clini-
cal trials and data reflecting our KS population. The
model assumed treatment of severe KS (CD4 (150) pa-
tients not previously treated with chemotherapy. It includes
direct cost associated with drug acquisition, physician mon-
itoring, administration of product, drug administration
cost, and treatment of complications. Probabilities and
direct cost data for nausea and vomiting, peripheral neur-
opathy, neutropenia, alopecia, and serious opportunistic
infections were included in the model. Drug cost reflects
dosing regimens currently in use: Daunoxom, 40 mg/m2
every 2 weeks, or Doxil, 20 mg/m2 every 2 weeks for six
cycles. Effectiveness was determined using the median du-
ration of response to therapy reported in clinical trials.
RESULTS: The cost effectiveness ratio for Daunoxome is
$24,263/median remission year versus $32,767 for
Doxil. One-way sensitivity analysis did not substantially
alter the results. The model also demonstrates Daunox-
orne to have a marginal cost advantage of $2,176
(20.9%) over Doxil.
CONCLUSION: The model identifies Daunoxome as the
most cost-effective and least expensive agent in the treat-
ment ofKS.
